These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21876341)

  • 21. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes.
    Schaarschmidt ML; Schmieder A; Umar N; Terris D; Goebeler M; Goerdt S; Peitsch WK
    Arch Dermatol; 2011 Nov; 147(11):1285-94. PubMed ID: 22106115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.
    Fernandez-Peñas P; Jones-Caballero M; Espallardo O; García-Díez A
    Br J Dermatol; 2012 Apr; 166(4):884-7. PubMed ID: 22229951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life in psoriasis: an analysis of Psocare project patients.
    Spandonaro F; Altomare G; Berardesca E; Calzavara-Pinton P; Chimenti S; Girolomoni G; Peserico A; Guerra AP; Vena GA; Polistena B; Ayala F
    G Ital Dermatol Venereol; 2011 Jun; 146(3):169-77. PubMed ID: 21566546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained improvement of the quality of life of patients with psoriasis after hospitalization.
    Vensel E; Hilley T; Trent J; Taylor JR; Kirsner RS; Kerdel FA; Taylor JR; Schwartzberg JB
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):858-60. PubMed ID: 11050595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive effect of modified Goeckerman regimen on quality of life and psychosocial distress in moderate and severe psoriasis.
    Chern E; Yau D; Ho JC; Wu WM; Wang CY; Chang HW; Cheng YW
    Acta Derm Venereol; 2011 Jun; 91(4):447-51. PubMed ID: 21537818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atorvastatin for the treatment of plaque-type psoriasis.
    Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
    Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between symptoms and patient characteristics among psoriasis patients.
    Bilac C; Ermertcan AT; Bilac DB; Deveci A; Horasan GD
    Indian J Dermatol Venereol Leprol; 2009; 75(5):551. PubMed ID: 19736461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between quality of life and the severity of psoriasis in Turkey.
    Çakmur H; Derviş E
    Eur J Dermatol; 2015 Apr; 25(2):169-76. PubMed ID: 25655046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study on the acceptance of mobile teledermatology for the home monitoring of high-need patients with psoriasis.
    Frühauf J; Schwantzer G; Ambros-Rudolph CM; Weger W; Ahlgrimm-Siess V; Salmhofer W; Hofmann-Wellenhof R
    Australas J Dermatol; 2012 Feb; 53(1):41-6. PubMed ID: 22309330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of vitiligo on self-reported health-related quality of life.
    Ongenae K; Van Geel N; De Schepper S; Naeyaert JM
    Br J Dermatol; 2005 Jun; 152(6):1165-72. PubMed ID: 15948977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a far erythemogenic dose of narrow-band ultraviolet B phototherapy in chronic plaque-type psoriasis.
    Akaraphanth R; Kittipavara Y; Voravutinon N; Wachiratarapadorn U; Gritiyarangsan P
    J Dermatol; 2010 Feb; 37(2):140-5. PubMed ID: 20175848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psoriasis has a major secondary impact on the lives of family members and partners.
    Eghlileb AM; Davies EE; Finlay AY
    Br J Dermatol; 2007 Jun; 156(6):1245-50. PubMed ID: 17459044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.
    Augustin M; Krüger K; Radtke MA; Schwippl I; Reich K
    Dermatology; 2008; 216(4):366-72. PubMed ID: 18319601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis.
    Hjortsberg C; Bergman A; Bjarnason A; Heikkilä H; Hjelmgren J; Svensson A; Tennvall GR
    Acta Derm Venereol; 2011 Jun; 91(4):409-14. PubMed ID: 21461549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
    Reich K; Griffiths CE
    Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea.
    Harari M; Novack L; Barth J; David M; Friger M; Moses SW
    Int J Dermatol; 2007 Oct; 46(10):1087-91. PubMed ID: 17910722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.